Lyme vaccine: Valneva completes recruitment for Phase 2 studies
by Press Release from Outbreak News Today on (#4RJFE)
Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, Monday announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15. A total of 819 subjects have been recruited for Phase 2 development in two ongoing studies. The results of ["]
The post Lyme vaccine: Valneva completes recruitment for Phase 2 studies appeared first on Outbreak News Today.